GLP-1 drops
Direct answer
What you need to know
Evidence strength: StrongNo GLP-1 receptor agonist is approved as an oral drop or tincture. Products under this name split into two very different groups: dietary supplements containing no medication, and unapproved liquid semaglutide sold with a “research use only” label. The first is mostly a waste of money. The second carries real risk, and the FDA has taken enforcement action over it.
Key takeaways
- Approved GLP-1 medications come as injections or oral tablets — not drops.
- Most drops are supplements: no semaglutide, no prescription needed, no drug effect.
- Some liquids are semaglutide, sold illegally with a research-use disclaimer.
- Unapproved products are not reviewed for identity, purity, sterility, or strength.
Important limitation: We cannot tell you which group any specific product falls into. That is the core problem: the label is the only thing distinguishing them at the point of sale, and the FDA has documented labels naming pharmacies that do not exist.
Next action: If you want a non-injectable GLP-1, the approved route is an oral tablet by prescription — see the format comparison.
Primary sources: U.S. Food & Drug Administration, U.S. Food & Drug Administration, DailyMed, U.S. National Library of Medicine, DailyMed, U.S. National Library of Medicine, U.S. Food & Drug Administration
General education, not medical advice. This page gives no sourcing or dosing guidance for unapproved products.
The two things sold under one name
Supplement drops — no medication
Herbal or botanical tinctures, often with the same ingredients found in GLP-1 gummies — berberine, cinnamon, apple cider vinegar. Sold openly, no prescription, and generally claiming to “support” your own GLP-1 rather than to contain the drug. Ineffective for the purpose most buyers have in mind, but not usually hazardous.
“Research use only” liquid semaglutide — the real risk
These may genuinely contain a GLP-1 receptor agonist. They are sold outside the prescription system with a disclaimer saying they are not for human consumption, frequently alongside dosing instructions that make the disclaimer meaningless. The FDA has issued warning letters to companies selling semaglutide, tirzepatide, and retatrutide this way.
Why no drop delivers a GLP-1, according to the only oral label
The usual claim attached to these products is sublingual — held under the tongue, absorbed straight into the blood, no injection needed. There is a reason no approved product works that way, and it is written into the prescribing information for the ones that are approved to be swallowed.
Semaglutide is a peptide, and peptides are broken down and poorly absorbed through the digestive tract. Making an oral version work took a co-formulated absorption enhancer, SNAC (salcaprozate sodium). The label is explicit about where the drug then crosses: absorption predominantly occurs in the stomach
. Not the mouth, and not under the tongue.
And even with the enhancer, and even absorbing where it was designed to, the label puts absolute bioavailability at approximately 0.4% to 1% for Rybelsus and 1% to 2% for Ozempic tablets. Put plainly: more than 99% of a swallowed dose never reaches the bloodstream, in the product specifically engineered to survive the trip. That is also why those tablets carry strict instructions about taking them fasting, with a sip of water, well before anything else.
A liquid dripped under the tongue has neither the enhancer nor the absorption site. So the answer to is there an FDA-approved GLP-1 drop
is no — and it is not a gap somebody has simply not filled yet. The one route that made oral delivery work at all needed a chemical escort and still gives up almost all of the dose.
Figures from the Rybelsus and Ozempic tablets prescribing information, clinical pharmacology section 12.3, label revised 1/2026.
Is there a drop version of the one you are looking for?
No, for every approved product. This is what each one actually comes as — two of them are swallowed, which is the closest an approved GLP-1 gets to what people mean by drops.
| Product | Molecule | How it is actually taken |
|---|---|---|
| Wegovy | semaglutide | weekly injection or daily tablet |
| Zepbound | tirzepatide | weekly injection |
| Foundayo | orforglipron | daily tablet |
| Ozempic | semaglutide | weekly injection |
| Mounjaro | tirzepatide | weekly injection |
| Rybelsus | semaglutide | daily tablet |
| Trulicity | dulaglutide | weekly injection |
| Victoza | liraglutide | daily injection |
| Saxenda | liraglutide | daily injection |
| Byetta | exenatide | twice-daily injection |
If what you actually want is a GLP-1 you swallow rather than inject, that exists and is prescribed: see the tablets, and what they give up.
Why the second group is dangerous in a specific way
- Nothing verifies what is in the bottle. Identity, concentration, sterility, and endotoxin levels are unreviewed. The FDA has documented fraudulent products whose labels name pharmacies that do not exist.
- Measuring a liquid dose yourself invites error. Confusion between millilitres, milligrams, and syringe “units” has caused overdoses requiring hospitalisation. See why we do not publish conversion instructions.
- Nobody screened you. The contraindications that come with a real prescription — thyroid cancer history, pancreatitis, pregnancy — are simply never asked about.
How to tell which one you are looking at
The most reliable signal is the one the seller cannot avoid: a real GLP-1 medication requires a prescription. If a liquid is available to buy directly, either it contains no GLP-1 drug, or it is being sold outside the system that exists to make it safe. Both are reasons not to buy it, for different reasons.
A “not for human consumption” label is not fine print to look past. It is the seller telling you, in writing, that the product was never intended to go into a person — which is also how they avoid the obligations that would apply if it were.
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- FDA intends to take action against non-FDA-approved GLP-1 drugsU.S. Food & Drug AdministrationSupports: FDA action against unapproved semaglutide, tirzepatide, and retatrutide sold direct to consumers, including products labelled for research use.
- FDA warns consumers not to use counterfeit Ozempic found in the U.S. drug supply chainU.S. Food & Drug AdministrationSupports: That counterfeit semaglutide has reached the legitimate supply chain, so provenance matters even outside obviously grey-market channels.
- RYBELSUS (semaglutide) tablets / OZEMPIC (semaglutide) tablets — prescribing informationDailyMed, U.S. National Library of MedicineSupports: Clinical pharmacology, section 12.3: semaglutide tablets are co-formulated with the absorption enhancer SNAC, absorption “predominantly occurs in the stomach”, and absolute bioavailability is approximately 0.4–1% (Rybelsus) and 1–2% (Ozempic tablets). Label revised 1/2026.
- FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: Approved dosage forms — no oral drop or tincture form exists for any GLP-1 receptor agonist.
- Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Prescription status and enforcement posture.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.